Results 11 to 20 of about 133,817 (310)

The Vigil Magnetometer for Operational Space Weather Services From the Sun‐Earth L5 Point [PDF]

open access: diamondSpace Weather
Severe space weather has the potential to cause significant socio‐economic impact and it is widely accepted that mitigating this risk requires more comprehensive observations of the Sun and heliosphere, enabling more accurate forecasting of significant ...
J. P. Eastwood   +12 more
doaj   +3 more sources

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer

open access: yesClinical Medicine Insights: Oncology, 2022
Background: Gemogenovatucel-T (Vigil) is a triple-function autologous tumor cell immunotherapy which expresses granulocyte-macrophage colony-stimulating factor and decreases expression of furin and downstream TGF-β1 and TGF-β2.
Phylicia A Aaron   +2 more
exaly   +3 more sources

Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials

open access: yesFrontiers in Oncology, 2022
In recent years, many clinical trials have shown the safety and efficacy of Gemogenovatucel-T (Vigil) in the treatment of advanced OC patients. The purpose of this study was to explore the safety and efficacy of Gemogenovatucel-T (Vigil) in the first ...
Yixin Zhang   +7 more
exaly   +4 more sources

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

open access: yesVaccines, 2021
Aim: To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil. Patients and Methods: Recurrent ovarian cancer patients (n = 21) enrolled in prior clinical trials.
Rodney P Rocconi   +2 more
exaly   +4 more sources

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product [PDF]

open access: yesScientific Reports
Retrospective data support overall survival (OS) advantage to high clonal tumor mutation burden (cTMB), high clonal neoantigen load (cNEO) and low intratumor heterogeneity (ITH) in cancer patients who receive immunotherapy.
David Willoughby   +10 more
doaj   +3 more sources

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy [PDF]

open access: bronzeFuture Oncology
We describe in this review the historical evidence leading up to the concept and design of Vigil and subsequent clinical applications including safety and efficacy in a randomized, controlled Phase IIB trial.
John J Nemunaitis   +2 more
exaly   +3 more sources

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6

open access: yesVaccines, 2021
Colorectal cancer is the third most diagnosed cancer in the United States. Five-year survival rates remain low and many patients will develop liver metastasis.
Vedin Barve   +8 more
doaj   +2 more sources

Extreme Space Weather Events of the Past 30 Years: Preparation for Data From Mission Vigil

open access: yesEarth and Space Science
Extreme Space Weather events can negatively affect ground‐based infrastructure and satellite communications. European Space Agency plans to launch a new operational mission, Vigil, to monitor space weather activity and provide timely warnings about ...
Adam Majirský   +3 more
doaj   +2 more sources

Vigil

open access: yesApparatus. Film, Media and Digital Cultures of Central and Eastern Europe, 2020
Tibor Hajas's video and article.
Tibor Hajas
doaj   +2 more sources

3D engineered scaffold for large-scale Vigil immunotherapy production

open access: yesScientific Reports
Previously, we reported successful cellular expansion of a murine colorectal carcinoma cell line (CT-26) using a three-dimensional (3D) engineered extracellular matrix (EECM) fibrillar scaffold structure.
John J Nemunaitis, Jörg Lahann
exaly   +2 more sources

Home - About - Disclaimer - Privacy